Michael G Brattain

Title: Michael G Brattain: Innovator in Cancer Diagnosis and Therapy

Introduction

Michael G Brattain is a notable inventor based in San Antonio, TX (US). He has made significant contributions to the field of cancer research, particularly in the area of cancer diagnosis and therapy. With a total of 3 patents, his work has the potential to impact the lives of many individuals affected by cancer.

Latest Patents

Brattain's latest patents focus on innovative methods for cancer diagnosis and therapy based on mutations in TGF-β receptors. One of his key inventions is centered around the discovery that the type II TGF-β receptor (RII) acts as a cancer suppressor gene. This gene is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers classified as mutator/microsatellite instability/RER. His methods provide a means for detecting the inactivation of RII, which can be utilized in cancer diagnosis or prognosis.

Career Highlights

Throughout his career, Brattain has worked with various institutions, including Case Western Reserve University. His research has been pivotal in advancing the understanding of cancer biology and developing new diagnostic tools.

Collaborations

Brattain has collaborated with esteemed colleagues such as Sanford D Markowitz and James K Willson. These partnerships have further enriched his research and contributed to the development of innovative cancer therapies.

Conclusion

Michael G Brattain's work exemplifies the critical role of inventors in advancing medical science. His patents and research efforts are paving the way for improved cancer diagnosis and treatment options.